SCHEMBL6444048

SCHEMBL6444048

CC(C)(C)OC(=O)NN(Cc1ccccc1)CC(O)C(Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.54
ABCB11 O95342 2/20 0.54
ABCB1 P08183 2/20 0.54
OPRK1 P41145 2/20 0.54
GHSR Q92847 2/20 0.54
ABCG2 Q9UNQ0 2/20 0.54
ABCC3 O15438 1/20 0.54
ABCC4 O15439 1/20 0.54
CACNA1F O60840 1/20 0.54
HTR1A P08908 1/20 0.54
DRD2 P14416 1/20 0.54
TACR2 P21452 1/20 0.54
TBXAS1 P24557 1/20 0.54
OPRM1 P35372 1/20 0.54
DRD3 P35462 1/20 0.54
AVPR1A P37288 1/20 0.54
OPRD1 P41143 1/20 0.54
HTR2B P41595 1/20 0.54
CACNA1D Q01668 1/20 0.54
SLC6A3 Q01959 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6444044 1.00 CYP3A4 (0.54) CYP3A4ABCB11ABCB1OPRK1GHSR
SCHEMBL6712827 0.91 CYP3A4 (0.53) CYP3A4ABCB11ABCB1OPRK1GHSR
SCHEMBL6445230 0.90 CYP3A4 (0.57) CYP3A4ABCB11ABCB1OPRK1GHSR
SCHEMBL6445233 0.90 CYP3A4 (0.57) CYP3A4ABCB11ABCB1OPRK1GHSR
SCHEMBL6443032 0.88 CTSD (0.49) CYP3A4ABCB11ABCB1OPRK1GHSR
SCHEMBL6443031 0.88 CTSD (0.49) CYP3A4ABCB11ABCB1OPRK1GHSR
SCHEMBL6947761 0.88 PSEN1 (0.46) ABCB11ABCB1OPRK1GHSRABCG2
SCHEMBL6711001 0.87 CYP3A4 (0.52) CYP3A4ABCB11ABCB1OPRK1GHSR
SCHEMBL6715023 0.87 CYP3A4 (0.58) CYP3A4ABCB11ABCB1OPRK1GHSR
SCHEMBL6444039 0.86 CCR1 (0.44) CYP3A4ABCB11ABCB1OPRK1GHSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050130941-A1 Methods of treating alzheimer's disease PHARMACIA & UPJOHN COMPANY LLC 2005-06-16 US disclosed
EP-1392315-A1 METHODS OF TREATING ALZHEIMER'S DISEASE Elan Pharmaceuticals, Inc. (US) 2004-03-03 EP disclosed
WO-2002100410-A1 METHODS OF TREATING ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2002-12-19 WO disclosed
EP-0604368-B1 Anti retroviral hydrazine derivatives CIBA GEIGY AG (CH) 1996-09-18 EP disclosed
EP-0604368-A1 Anti retroviral hydrazine derivatives CIBA-GEIGY AG (CH) 1994-06-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130941-A1 Methods of treating alzheimer's disease BACE1, PSEN1, BACE2 CYP3A4 2875/4885ABCB11 3438/4885ABCB1 1675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.